-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Attention Deficit Hyperactivity Disorder (ADHD) Market Report Overview The ADHD market across the 7MM was valued at $11.9 billion in 2022. The market will decline at a CAGR of less than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with specific criteria for children and adults. ADHD is characterized by age-inappropriate, extreme, and impairing levels of inattention and/or hyperactivity and impulsivity. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Teriparatide in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Teriparatide in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Teriparatide in Osteoporosis Drug Details: Teriparatide (MicroCor hPTH (1-34)) is under development for...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewOsteoporosis – Drugs In Development, 2024
Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than...
-
Product Insights
Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Transdermal Drug Delivery Pipeline Market Report Overview Transdermal drug delivery devices are medicated adhesive patches placed on the skin to deliver a specific dose of medication through the skin into the bloodstream. The Transdermal Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials,...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Sector Analysis
Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Alzheimer’s Disease Market Overview The total AD and MCI market was $2.2 billion across the 8MM in 2020 and will achieve a CAGR of more than 20% during 2020-2030. The launch of 23 new therapies, including several drug candidates that have the potential to modify the underlying cause of the disease will drive market growth during the forecast period. Alzheimer’s Disease Market Outlook, 2020-2030 ($ Billion) Buy the Full Report to Gain More Information on the Alzheimer’s Disease Market Forecast...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – teriparatide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry teriparatide Drug Details Teriparatide (MicroCor hPTH (1-34)) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – memantine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry memantine Drug Details Memantine is under development for the treatment of Alzheimer's disease. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – teriparatide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry teriparatide Drug Details EB-612 is under development for the treatment of hypoparathyroidism. The drug...